Evidence map›Paper›PMID 39901182›Full record

ArticleJournal of cheminformatics2025

PretoxTM: a text mining system for extracting treatment-related findings from preclinical toxicology reports.

Javier Corvi, Nicolás Díaz-Roussel, José M Fernández, Francesco Ronzano, Emilio Centeno, Pablo Accuosto, Celine Ibrahim, Shoji Asakura, Frank Bringezu, Mirjam Fröhlicher and 12 more

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Javier CorviLife Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain. javier.corvi@disgenet.com.
Nicolás Díaz-RousselLife Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain.
José M FernándezLife Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain.
Francesco RonzanoHospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Emilio CentenoHospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Pablo AccuostoMedBioInformatics Solutions, Barcelona, Spain.
Celine IbrahimBayer AG, In Vitro Safety, Berlin, Germany.
Shoji AsakuraEisai, Tsukuba, Ibaraki, Japan.
Frank BringezuChemical and Preclinical Safety, Merck Healthcare KGaA, Darmstadt, Germany.
Mirjam FröhlicherTranslational Medicine, Preclinical Safety, Novartis Biomedical Research, Basel, Switzerland.
Annika KreuchwigBayer AG, In Vitro Safety, Berlin, Germany.
Yoko NogamiEisai, Tsukuba, Ibaraki, Japan.
Jeong RihIpsen Innovation, Les Ulis, France.
Raul Rodriguez-EstebanRoche Innovation Center Basel, Basel, Switzerland.
Nicolas SajotServier, Gif-sur-Yvette, France.
Joerg WichardBayer AG, In Vitro Safety, Berlin, Germany.
Heng-Yi Michael WuGenentech Research and Early Development (gRED) Computational Sciences, Genentech, Inc., South San Francisco, CA, USA.
Philip DrewPDS Consultants, Leicester, UK.
Thomas Steger-HartmannBayer AG, In Vitro Safety, Berlin, Germany.
Alfonso ValenciaLife Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain.
Laura I FurlongMedBioInformatics Solutions, Barcelona, Spain.
Salvador Capella-GutierrezLife Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain. salvador.capella@bsc.es.

Funding

eTRANSAFE (IMI2, Horizon 2020 and EFPIA) 77365
6 · The paper itself

Abstract

Over the last few decades the pharmaceutical industry has generated a vast corpus of knowledge on the safety and efficacy of drugs. Much of this information is contained in toxicology reports, which summarise the results of animal studies designed to analyse the effects of the tested compound, including unintended pharmacological and toxic effects, known as treatment-related findings. Despite the potential of this knowledge, the fact that most of this relevant information is only available as unstructured text with variable degrees of digitisation has hampered its systematic access, use and exploitation. Text mining technologies have the ability to automatically extract, analyse and aggregate such information, providing valuable new insights into the drug discovery and development process. In the context of the eTRANSAFE project, we present PretoxTM (Preclinical Toxicology Text Mining), the first system specifically designed to detect, extract, organise and visualise treatment-related findings from toxicology reports. The PretoxTM tool comprises three main components: PretoxTM Corpus, PretoxTM Pipeline and PretoxTM Web App. The PretoxTM Corpus is a gold standard corpus of preclinical treatment-related findings annotated by toxicology experts. This corpus was used to develop, train and validate the PretoxTM Pipeline, which extracts treatment-related findings from preclinical study reports. The extracted information is then presented for expert visualisation and validation in the PretoxTM Web App.Scientific ContributionWhile text mining solutions have been widely used in the clinical domain to identify adverse drug reactions from various sources, no similar systems exist for identifying adverse events in animal models during preclinical testing. PretoxTM fills this gap by efficiently extracting treatment-related findings from preclinical toxicology reports. This provides a valuable resource for toxicology research, enhancing the efficiency of safety evaluations, saving time, and leading to more effective decision-making in the drug development process.

Indexed as

Adverse effectAnimal modelAnnotated corporaCompoundDrugNatural language processingPreclinicalText miningToxicology

Identifiers

PMID39901182
PMCPMC11792311

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.